Hydron;1-(oxetan-3-yl)ethanamine;chloride | 2055842-00-5

• 物质功能分类: 医药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 环氧化物
• 英文名称: Hydron;1-(oxetan-3-yl)ethanamine;chloride
• CAS: 2055842-00-5
• 化学式: C5H12ClNO
• 分子量: 137.61
• InChiKey: YEUAWPRZTGNTRH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.2
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] SUBSTITUTED PYRROLOPYRIDINE-DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRROLOPYRIDINE SUBSTITUÉS
  申请人：BAYER PHARMA AG

  公开号：WO2019016071A1

  公开（公告）日：2019-01-24

  The present invention relates to protein-inhibitory substituted pyrrolopyridine derivatives of formula (I), in which A, X, R1, R2a, R2b, R3a, R3b, R4a and R4b are as defined herein, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, repectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients. The present invention further relates to the use, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control.

  本发明涉及式(I)的蛋白抑制取代吡咯吡啶衍生物，其中A、X、R1、R2a、R2b、R3a、R3b、R4a和R4b如本文所定义，以及包含根据本发明的化合物的药物组合物和药物组合物，以及创新化合物的预防和治疗用途，分别用于制造用于治疗或预防疾病的药物组合物，特别是用于肿瘤性疾病、癌症或与MAP4K1信号异常相关的其他疾病的治疗或预防，作为单一药剂或与其他活性成分组合使用。本发明还涉及用途，分别用于制造用于治疗或预防良性增生、动脉粥样硬化疾病、败血症、自身免疫性疾病、血管疾病、病毒感染、神经退行性疾病、炎症性疾病、动脉粥样硬化疾病和男性生育控制的蛋白抑制剂的药物组合物。
• SUBSTITUTED PYRROLOPYRIDINE-DERIVATIVES
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：EP3655406A1

  公开（公告）日：2020-05-27